Biologics, drugs manufactured thorough the techniques of modern biotechnology, represent a large and growing share of the U.S. drug market and offer the promise of treating disease and conditions for which there is no other cure. But they are expensive to develop and produce and, in contrast to other types of drugs, no one can make a precisely identical generic to compete with the original maker. To help foster competition, Congress created a pathway for “biosimilars,” including products demonstrated to be interchangeable (though not identical) to the original. But competition from biosimilars has been slower to develop in the U.S. than in Europe and the savings from competition that does occur in the U.S. hasn’t always led to lower prices for patients or insurers.
On July 18, the USC-Brookings Schaeffer Initiative for Health Policy and the Hutchins Center on Fiscal & Monetary Policy at Brookings hosted Food & Drug Administration Commissioner Scott Gottlieb for a discussion of biosimilars, which have been a major focus of the FDA’s efforts to increase competition and choice for patients and the U.S. healthcare system. Following his presentation, Dr. Gottlieb was interviewed by David Wessel, director of the Hutchins Center, and will take questions. Then a panel of experts responded to Dr. Gottlieb and discussed related issues in the pharmaceutical market. The event was webcast.
Join the conversation on Twitter with #biosimilars
- Event Date
- Wednesday, July 18, 2018
1:30 PM - 3:00 PM Eastern
- Brookings Institution
1775 Massachusetts Avenue - NW
- Scott Gottlieb, Commissioner, Food and Drug Administration
- Leemore Dafny, Bruce V. Rauner Professor of Business Administration - Harvard Business School
- Arti Rai, Professor, Duke University
- Joshua Ofman, Senior Vice President, Global Value Access & Policy, Amgen
- Moderator: David Wessel, Director, The Hutchins Center for Fiscal and Monetary Policy, Senior Fellow - Economic Studies